The South East Asia COVID-19 molecular diagnostics market size is expected to reach USD 1.54 billion by 2030. The market is expected to register a CAGR of -5.20% from 2023 to 2030. Diagnostics for COVID-19 were developed as a result of the sudden exponential increase in COVID-19 cases.
An increase in funding and investments by various private & public organizations to boost the development of COVID-19 diagnostic tests is anticipated to support market growth. In December 2020, the Global Fund announced that it would further provide extra funding of USD 10.6 million to Myanmar under COVID-19 Response Mechanism (C19RM). Furthermore, in September 2020, a group of healthcare organizations and test manufacturers established a set of agreements to make 120 million rapid tests available for low- and middle-income countries at a reasonable price.
In response to the COVID-19 pandemic, many diagnostic test developers are focusing on the development of fast and easy-to-use diagnostic tests to facilitate rapid testing. For instance, in May 2022, Labcorp received FDA approval for its Labcorp Seasonal Respiratory Virus RT-PCR DTC Test for usage by people without a prescription who have respiratory viral infection symptoms that are consistent with SARS-CoV-2. Moreover, in May 2022, Becton, Dickinson and Company launched a novel high-throughput molecular diagnostic test to detect and differentiate influenza A/B or SARS-CoV-2. This novel test uses a single nasopharyngeal swab or single nasal swab to identify if a patient has the flu, SARS-CoV-2 or RSV.
In response to the pandemic, companies are undertaking several initiatives such as partnerships, collaborations, and geographic expansion for strengthening their market position. For instance, in March 2022, iGene Laboratory announced the launch of its new saliva-based PCR test for SARS-CoV-2 virus detection. The company has entered into partnerships with clinics to consolidate its distribution channel.
Rapidly spreading awareness about preventive measures for SARS-CoV-2 virus infections and the increased rate of vaccinations has played a prominent role in declining COVID-19 cases in Southeast Asia. According to the WHO, as of January 2023, 3,299 million total doses were administered in South East Asia. Moreover, 1,520 million individuals were vaccinated with COVID-19 single dose. Rising COVID-19 vaccination decreases the overall COVID-19 cases in the South East Asian countries, thus slowing down the growth of the market.
An increase in funding and investments by various private & public organizations to boost the development of COVID-19 diagnostic tests is anticipated to support market growth. In December 2020, the Global Fund announced that it would further provide extra funding of USD 10.6 million to Myanmar under COVID-19 Response Mechanism (C19RM). Furthermore, in September 2020, a group of healthcare organizations and test manufacturers established a set of agreements to make 120 million rapid tests available for low- and middle-income countries at a reasonable price.
In response to the COVID-19 pandemic, many diagnostic test developers are focusing on the development of fast and easy-to-use diagnostic tests to facilitate rapid testing. For instance, in May 2022, Labcorp received FDA approval for its Labcorp Seasonal Respiratory Virus RT-PCR DTC Test for usage by people without a prescription who have respiratory viral infection symptoms that are consistent with SARS-CoV-2. Moreover, in May 2022, Becton, Dickinson and Company launched a novel high-throughput molecular diagnostic test to detect and differentiate influenza A/B or SARS-CoV-2. This novel test uses a single nasopharyngeal swab or single nasal swab to identify if a patient has the flu, SARS-CoV-2 or RSV.
In response to the pandemic, companies are undertaking several initiatives such as partnerships, collaborations, and geographic expansion for strengthening their market position. For instance, in March 2022, iGene Laboratory announced the launch of its new saliva-based PCR test for SARS-CoV-2 virus detection. The company has entered into partnerships with clinics to consolidate its distribution channel.
Rapidly spreading awareness about preventive measures for SARS-CoV-2 virus infections and the increased rate of vaccinations has played a prominent role in declining COVID-19 cases in Southeast Asia. According to the WHO, as of January 2023, 3,299 million total doses were administered in South East Asia. Moreover, 1,520 million individuals were vaccinated with COVID-19 single dose. Rising COVID-19 vaccination decreases the overall COVID-19 cases in the South East Asian countries, thus slowing down the growth of the market.
South East Asia COVID-19 Molecular Diagnostics Market Report Highlights
- The reagents & kits segment held the largest share in 2022, as they are key components of SARS-CoV-2 testing. The emerging variants of the SARS-CoV-2 virus are expected to boost the uptake of reagents & kits
- The instrument segment is expected to decline in the coming years owing to decreasing testing globally, as the number of vaccinated people has significantly grown
- By technology, the PCR segment dominated the segment in 2022. Among various technologies, quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) is considered the gold standard and is used across several laboratory settings in South East Asia
- Laboratory testing held a major share in 2022. Laboratory diagnosis of coronavirus is extremely necessary for outbreak and disease management. At the onset of the pandemic, several laboratories in South East Asia were working on conducting tests at a high scale
- For instance, in June 2020, according to the data published by WHO, a COVID-19 testing facility was built in the Maldives, which could timely detect and roll out a response to COVID-19 cases. Approximately 700 samples could be tested per day, and the capacity would further be scaled up
- Singapore dominated the SEA COVID-19 molecular diagnostics market in 2022 due to the most organized epidemic control systems and robust support from the government for enhancing the SARS-CoV-2 testing capacity of the region
Table of Contents
Chapter 1 Methodology and Scope1.1 Market Segmentation
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.4.1 Primary Sources
1.3.4.2 Secondary Data Sources
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Market Model
1.7 Objectives
1.7.1 Objective 1
1.7.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
2.4 COVID-19 Diagnostics Market: Market Summary
Chapter 3 Market Variables, Trends, & Scope
3.1 South East Asia COVID-19 Molecular Diagnostics Market Lineage Outlook
3.1.1 Parent Market
3.2 Penetration & Growth Prospect Mapping for Technology, 2022
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Increasing product approvals by regulatory agencies
3.3.1.2 Paradigm shift toward POC testing
3.3.2 Market restraint analysis
3.3.2.1 Decline in COVID-19 cases
3.3.2.2 Increasing number of vaccinated people
3.3.3 Market opportunity analysis
3.3.3.1 Potential emerging markets
3.3.3.2 Increasing penetration of telehealth for diagnosis of COVID-19
3.3.4 Market Challenge analysis
3.3.4.1 Challenges pertaining to COVID-19 testing in healthcare settings
3.4 South East Asia COVID-19 Molecular Diagnostics Market - Business environment analysis
3.4.1 Porter’s five forces analysis
3.4.2 SWOT analysis; by factor (political & legal, economic and technological)
3.4.2.1 Political and Legal
3.4.2.1.1 Strengths
3.4.2.1.2 Weaknesses
3.4.2.1.3 Opportunities
3.4.2.1.4 Threats
3.4.2.2 Economic
3.4.2.2.1 Strengths
3.4.2.2.2 Weakness
3.4.2.2.3 Opportunity
3.4.2.2.4 Threat
3.4.2.3 Technological
3.4.2.3.1 Strengths
3.4.2.3.2 Weakness
3.4.2.3.3 Opportunity
3.4.2.3.4 Threat
3.5 South East Asia COVID-19 Molecular Diagnostics Market: Company Position Analysis
3.6 South East Asia COVID-19 Molecular Diagnostics Market - Regulatory Framework
3.7 Effect on Swabs Market
3.7.1 Production shortage for viral transport media
3.7.2 Companies leading the viral transport media market
3.7.2.1 COPAN Diagnostics
3.7.2.2 Puritan Medical Products
3.7.2.3 Becton, Dickinson and Company (BD)
3.7.2.4 Thermo Fisher Scientific
3.7.2.5 Other emerging companies
Chapter 4 Product Business Analysis
4.1 South East Asia COVID-19 Molecular Diagnostics Market: Product Movement Analysis
4.1.1 Reagents & Kits
4.1.1.1 Reagents & kits market estimates and forecast, 2020 - 2030 (USD Million)
4.1.2 Instruments
4.1.2.1 Instruments market estimates and forecast, 2020 - 2030 (USD Million)
Chapter 5 Technology Business Analysis
5.1 South East Asia COVID-19 Molecular Diagnostic Market: Technology Movement Analysis
5.1.1 PCR Testing
5.1.1.1 PCR testing market estimates and forecast, 2020 - 2030 (USD Million)
5.1.2 Other Technologies
5.1.2.1 Other technologies market estimates and forecast, 2020 - 2030 (USD Million)
Chapter 6 End-User Business Analysis
6.1 South East Asia COVID-19 Molecular Diagnostics Market: End-Use Movement Analysis
6.1.1 Laboratories
6.1.1.1 Laboratories market estimates and forecast, 2020 - 2030 (USD Million)
6.1.2 Hospitals
6.1.2.1 Hospitals market estimates and forecast, 2020 - 2030 (USD Million)
6.1.3 Diagnostic Centers and Clinics
6.1.3.1 Diagnostic centers and clinics market estimates and forecast, 2020 - 2030 (USD Million)
6.1.4 Research Institutes
6.1.4.1 Research institutes market estimates and forecast, 2020 - 2030 (USD Million)
Chapter 7 Regional Business Analysis
7.1 South East Asia COVID-19 Molecular Diagnostics Market Share by Regional, 2022 & 2030
7.2 South East Asia
7.2.1 SWOT Analysis
7.2.1.1 South East Asia COVID-19 molecular diagnostics market, by product
7.2.1.2 South East Asia COVID-19 molecular diagnostics market, by technology
7.2.1.3 South East Asia COVID-19 molecular diagnostics market, by end-user
7.2.2 Brunei
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Brunei market estimates and forecast, 2020 - 2030 (USD Million)
7.2.3 Cambodia
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 Cambodia market estimates and forecast, 2020 - 2030 (USD Million)
7.2.4 Indonesia
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 Indonesia market estimates and forecast, 2020 - 2030 (USD Million)
7.2.5 Laos
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Laos market estimates and forecast, 2020 - 2030 (USD Million)
7.2.6 Malaysia
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Malaysia market estimates and forecast, 2020 - 2030 (USD Million)
7.2.7 Singapore
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Singapore market estimates and forecast, 2020 - 2030 (USD Million)
7.2.8 Philippines
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Philippines market estimates and forecast, 2020 - 2030 (USD Million)
7.2.9 Vietnam
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Vietnam market estimates and forecast, 2020 - 2030 (USD Million)
7.2.10 Thailand
7.2.10.1 Key Country Dynamics
7.2.10.2 Target Disease Prevalence
7.2.10.3 Competitive Scenario
7.2.10.4 Regulatory Framework
7.2.10.5 Reimbursement Scenario
7.2.10.6 Thailand market estimates and forecast, 2020 - 2030 (USD Million)
7.2.11 Myanmar
7.2.11.1 Key Country Dynamics
7.2.11.2 Target Disease Prevalence
7.2.11.3 Competitive Scenario
7.2.11.4 Regulatory Framework
7.2.11.5 Reimbursement Scenario
7.2.11.6 Myanmar market estimates and forecast, 2020 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Participant’s overview
8.2 Financial performance
8.3 Participation Categorization
8.3.1 Market Leaders
8.3.2 South East Asia COVID-19 Molecular Diagnostics Market
8.3.3 Company Profiles
8.3.3.1 Thermo Fisher Scientific, Inc.
8.3.3.2 F. Hoffmann-La Roche AG
8.3.3.3 PerkinElmer, Inc
8.3.3.4 Neuberg Diagnostics
8.3.3.5 1drop, Inc.
8.3.3.6 Veredus Laboratories Pte Ltd.
8.3.3.7 ADT BiotecH
8.3.3.8 Altona Diagnostics GmbH.
8.3.3.9 bioMérieux SA
8.3.3.10 Danaher Corporation
8.3.3.11 Mylab Discovery Solutions Pvt. Ltd
8.3.3.12 ALDATU BIOSCIENCES
8.3.3.13Quidel Corporation
8.3.3.14 Quest diagnostics
8.3.3.15 Hologic, Inc.
8.3.3.16 Laboratory Corporation of America Holdings
8.3.3.17 Luminex Corporation
8.3.3.18 Quest diagnostics
8.3.3.19 Abbott
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 South East Asia COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 4 South East Asia COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 5 South East Asia COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 6 Brunei COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 7 Brunei COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 8 Brunei COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 9 Cambodia COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 10 Cambodia COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 11 Cambodia COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 12 Indonesia COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 13 Indonesia COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 14 Indonesia COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 15 Laos COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 16 Laos COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 17 Laos COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 18 Malaysia COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 19 Malaysia COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 20 Malaysia COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 21 Myanmar COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 22 Myanmar COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 23 Myanmar COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 24 Philippines COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 25 Philippines COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 26 Philippines COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 27 Singapore COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 28 Singapore COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 29 Singapore COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 30 Thailand COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 31 Thailand COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 32 Thailand COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
Table 33 Vietnam COVID-19 Molecular Diagnostics Market, By Product, 2020 - 2030 (USD Million)
Table 34 Vietnam COVID-19 Molecular Diagnostics Market, By Technology, 2020 - 2030 (USD Million)
Table 35 Vietnam COVID-19 Molecular Diagnostics Market, By End-user, 2020 - 2030 (USD Million)
List of Figures
Fig. 1 Market segmentation & scope
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 South East Asia COVID-19 molecular diagnostics market estimation process
Fig. 13 Penetration & growth prospect mapping for technology, 2022
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s analysis
Fig. 17 Company position analysis
Fig. 18 South East Asia COVID-19 molecular diagnostics market: Product outlook and key takeaways
Fig. 19 South East Asia COVID-19 molecular diagnostics market: Product movement analysis
Fig. 20 Reagents & kits market estimates and forecast, 2020 - 2030 (USD million)
Fig. 21 Instruments market estimates and forecast,2020 - 2030 (USD million)
Fig. 22 South East Asia COVID-19 molecular diagnostics market: Technology type outlook and key takeaways
Fig. 23 South East Asia COVID-19 molecular diagnostics market: Technology movement analysis
Fig. 24 PCR testing market estimates and forecast, 2020 - 2030 (USD million)
Fig. 25 Other technologies market estimates and forecast, 2020 - 2030 (USD million)
Fig. 26 South East Asia COVID-19 molecular diagnostics market: End-use outlook and key takeaways
Fig. 27 South East Asia COVID-19 molecular diagnostics market: end-use movement analysis
Fig. 28 Laboratories market estimates and forecast, 2020 - 2030 (USD million)
Fig. 29 Hospitals market estimates and forecast, 2020 - 2030 (USD million)
Fig. 30 Diagnostic centers and clinics market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 31 Research institutes market estimates and forecast, 2020 - 2030 (USD million)
Fig. 32 South East Asia COVID-19 molecular diagnostics market: Regional outlook and key takeaways
Fig. 33 South East Asia COVID-19 Molecular Diagnostics Market: Regional outlook, 2021 & 2030
Fig. 34 South East Asia market estimates and forecast, 2020 - 2030 (USD million)
Fig. 35 COVID-19 cases trends in Brunei
Fig. 36 Brunei market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 37 COVID-19 cases trends in Cambodia
Fig. 38 Cambodia Market Estimates And Forecast, 2020 - 2030 (USD Million)
Fig. 39 COVID-19 cases trends in Indonesia
Fig. 40 Indonesia market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 41 Total COVID-19 tests per 1,000 people in Laos (As of 9 June 2022)
Fig. 42 COVID-19 cases trends in Laos
Fig. 43 Laos market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 44 COVID-19 cases trends in Malaysia
Fig. 45 Malaysia market estimates and forecast, 2020 - 2030 (USD Million)
Fig. 46 Active COVID-19 cases in Singapore
Fig. 47 Singapore Market Estimates And Forecast, 2020 - 2030 (USD Million)
Fig. 48 Philippines Market Estimates And Forecast, 2020 - 2030 (USD Million)
Fig. 49 Active COVID-19 cases in Vietnam
Fig. 50 Vietnam Market Estimates And Forecast, 2020 - 2030 (USD Million))
Fig. 51 Thailand Market Estimates And Forecast, 2020 - 2030 (USD Million))
Fig. 52 Active COVID-19 cases in Myanmar
Fig. 53 Myanmar Market Estimates And Forecast, 2020 - 2030 (USD Million)
Fig. 54 Company/Competition categorization (key innovators, market leaders, & emerging players)
Fig. 55 Strategy framework
Fig. 56 Market participation categorization
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche AG
- PerkinElmer, Inc
- Neuberg Diagnostics
- 1drop, Inc.
- Veredus Laboratories Pte Ltd.
- ADT BiotecH
- Altona Diagnostics GmbH.
- bioMérieux SA
- Danaher Corporation
- Mylab Discovery Solutions Pvt. Ltd
- ALDATU BIOSCIENCES
- Quidel Corporation
- Quest diagnostics
- Hologic, Inc.
- Laboratory Corporation of America Holdings
- Luminex Corporation
- Quest diagnostics
- Abbott
Methodology
LOADING...
